About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Promising Oxford Covid Vaccine

by Jeffil Obadiah on July 17, 2020 at 7:08 AM
Font : A-A+

Promising Oxford Covid Vaccine

Covid-19 vaccine developed at Oxford University generated an immune response against the disease in Phase-1 trial which has given the researchers a Promising start.

The Oxford vaccine candidate is believed to be leading the race among over 100 to find an effective protection against the disease.

Advertisement


Oxford scientists have found that the jab triggers a response that may offer a "double defence" against SARS-CoV-2, the virus that causes Covid-19, The Telegraph report said on Wednesday.

The vaccine was developed at the University of Oxford's Jenner Institute.

Oxford in April announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the Covid-19 vaccine candidate.
Advertisement

While the Phase-1 trial of the vaccine candidate began in April itself, a start of the Phase2/Phase-3 UK trial of the Oxford vaccine, named AZD1222, in about 10,000 adult volunteers, was announced in May.

However, the results of the Phase-1 trial were still awaited.

In June, Astrazeneca CEO Pascal Soriot told Belgian radio station Bel RTL that the Oxford vaccine will likely provide protection against the disease for one year.

"We think it will protect for about a year," Soriot was quoted as saying.

According to a report in City A.M., AstraZeneca is aiming to deliver two billion doses of the drug by the end of the year.

The drugmaker had earlier said it had reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford's Covid-19 vaccine, with deliveries starting by the end of 2020.

The company completed similar agreements with the UK, the US, the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance for 700 million doses, and it agreed a licence with the Serum Institute of India for the supply of an additional one billion doses, principally for low- and middle-income countries.

Source: IANS
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Monkeypox Outbreak: What it is, How Does it Spread & the Prevention
Seasonal Allergy Medications
How to Choose the Best Eczema-Friendly Moisturizer for Children?
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Vaccination for Children Top 10 Vaccine Myths Debunked Green Fungus Post-COVID Syndrome Multisystem Inflammatory Syndrome (MIS-C) Omicron Variant of COVID-19 

Most Popular on Medindia

A-Z Drug Brands in India Hearing Loss Calculator Find a Hospital Accident and Trauma Care Drug Side Effects Calculator Loram (2 mg) (Lorazepam) Iron Intake Calculator Drug - Food Interactions Blood Donation - Recipients Indian Medical Journals

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use